Payment overview · 2025
General Payments
$20.90
1 reported records · 1 companies
Healthcare provider profile · identity verified
Caryl Guillermo, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEBSTER, TX · NPI 1093043358
Verified facts
What the public records show
CMS Open Payments records show Caryl Guillermo, MD received $20.90 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.90 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $20.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 79 |
| Losartan Potassium | Losartan Potassium | 234 | 69 |
| Sertraline Hcl | Sertraline Hcl | 190 | 43 |
| Simvastatin | Simvastatin | 182 | 48 |
| Gabapentin | Gabapentin | 175 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 43 |
| Metformin Hcl | Metformin Hcl | 170 | 51 |
| Lisinopril | Lisinopril | 169 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 43 |
| Metformin Hcl Er | Metformin Hcl | 145 | 45 |
| Omeprazole | Omeprazole | 130 | 44 |
| Furosemide | Furosemide | 129 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 126 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 32 |
| Meloxicam | Meloxicam | 98 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 28 |
| Tramadol Hcl | Tramadol Hcl | 91 | 32 |
| Clonazepam | Clonazepam | 89 | 22 |
| Mounjaro | Tirzepatide | 89 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 35 |
| Pregabalin | Pregabalin | 85 | 22 |
| Ozempic | Semaglutide | 82 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 28 |
| Montelukast Sodium | Montelukast Sodium | 80 | 26 |
| Potassium Chloride | Potassium Chloride | 75 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 74 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 31 |
| Carvedilol | Carvedilol | 68 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 18 |
| Ibuprofen | Ibuprofen | 64 | 21 |
| Famotidine | Famotidine | 59 | 26 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Eliquis | Apixaban | 55 | 13 |
| Methylprednisolone | Methylprednisolone | 55 | 49 |
| Allopurinol | Allopurinol | 54 | 17 |
| Glimepiride | Glimepiride | 54 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 15 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Diazepam | Diazepam | 49 | 18 |
| Bupropion Xl | Bupropion Hcl | 48 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 14 |
| Buspirone Hcl | Buspirone Hcl | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 25 |
| Celecoxib | Celecoxib | 40 | 11 |
| Azelastine Hcl | Azelastine Hcl | 39 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 15 |
| Cefdinir | Cefdinir | 37 | 29 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 14 |
| Valsartan | Valsartan | 33 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Alprazolam | Alprazolam | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 15 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 19 |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Fluconazole | Fluconazole | 21 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 12 |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $20.90 · 1 records | ABBVIE INC. | — | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error